Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 1:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo - Capsule Clear all
Completed Phase 1Phase 2 Interventional Results available

Use of Oral Probiotics to Reduce Urinary Oxalate Excretion

NCT00587041
View directory record Official record
Conditions
Nephrolithiasis, Hyperoxaluria, Crohn's Disease
Interventions
Oxadrop, Agri-King Synbiotic (AKSB), Placebo
Dietary Supplement · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 30, 2012 · Synced Sep 21, 2026, 1:03 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

A Trial of Dyanavel XR in Treating Co-occurring Fatigue Symptoms in Adults With Attention Deficit Hyperactivity Disorder (ADHD).

NCT06248229
View directory record Official record
Conditions
Fatigue, Attention Deficit Hyperactivity Disorder, Attention Deficit Disorder
Interventions
Dyanavel XR, Placebo
Drug
Lead sponsor
Rochester Center for Behavioral Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Rochester Hills, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Sep 21, 2026, 1:03 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Sonication-based OCD Neurosurgical Intervention Via Capsulotomy

NCT06131502
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
ExAblate MR-guided Focused Ultrasound Bilateral Anterior Capsulotomy
Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
25 Years to 64 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
2
States / cities
Palo Alto, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Sep 21, 2026, 1:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Somato® (Phytomelatonin) Versus Synthetic Melatonin and Placebo on Sleep Quality

NCT07669766
View directory record Official record
Conditions
Sleep
Interventions
Plant-based melatonin, Melatonin, Placebo
Dietary Supplement
Lead sponsor
Nutraland USA, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
244 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 21, 2026, 1:03 PM EDT
Recruiting Phase 1Phase 2 Interventional

Combination Upper-Airway Electrical and Pharmacological Stimulation for Obstructive Sleep Apnea

NCT07577661
View directory record Official record
Conditions
Obstructive Sleep Apnea, Sleep-disordered Breathing
Interventions
Combination device and drug: Unilateral hypoglossal nerve stimulation & atomoxetine-plus-oxybutynin (HGNS+AtoOxy), Unilateral hypoglossal nerve stimulation (HGNS), active comparator condition, Atomoxetine-plus-oxybutynin (80/5 mg) (AtoOxy), active comparator condition, Placebo; placebo comparator condition
Other · Device · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 79 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 20, 2026 · Synced Sep 21, 2026, 1:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Crossover Study of Neuropsychological Effects of Lacosamide and Carbamazepine Immediate Release in Healthy Subjects

NCT01530022
View directory record Official record
Conditions
Healthy
Interventions
Lacosamide (LCM), Carbamazepine Immediate Release (CBZ-IR)
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
2
States / cities
Atlanta, Georgia • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2014 · Synced Sep 21, 2026, 1:03 PM EDT
Completed Not applicable Interventional

Effects of Dietary Supplement Tauroursodeoxycholic Acid on Vascular Function

NCT03331432
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Tauroursodeoxycholic acid, Placebo
Dietary Supplement
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
20 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 18, 2018 · Synced Sep 21, 2026, 1:03 PM EDT
Completed Phase 2 Interventional

Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction

NCT06017609
View directory record Official record
Conditions
Chronic Heart Failure
Interventions
JTT-861 Capsules, Placebo Capsules
Drug
Lead sponsor
Akros Pharma Inc.
Industry
Eligibility
30 Years to 85 Years
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
20
States / cities
Phoenix, Arizona • Crystal River, Florida • Hialeah, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 21, 2026, 1:03 PM EDT
Completed Phase 2 Interventional

Talampanel for Amyotrophic Lateral Sclerosis (ALS)

NCT00696332
View directory record Official record
Conditions
ALS
Interventions
Talampanel, placebo
Drug · Other
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
559 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
7
States / cities
San Francisco, California • Kansas City, Kansas • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2011 · Synced Sep 21, 2026, 1:03 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Trial of an Intervention to Improve Metformin Persistence and Adherence

NCT03467763
View directory record Official record
Conditions
Metformin Adverse Reaction, Tolerance
Interventions
Metformin Extended Release Oral Tablet, Placebo oral capsule
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 100 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 6, 2020 · Synced Sep 21, 2026, 1:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of the Combination of Nitrate and Caffeine on Critical Power In Trained Male Cyclists

NCT07501806
View directory record Official record
Conditions
Exercise Performance of Fit Athletes, Exercise Performance, Cycling Performance
Interventions
Dietary Nitrate, Caffeine, Placebo
Dietary Supplement · Other
Lead sponsor
Lindenwood University
Other
Eligibility
18 Years to 40 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Sep 21, 2026, 1:03 PM EDT
Active, not recruiting Phase 2 Interventional

Clavulanic Acid for the Treatment of Cocaine Use Disorder

NCT05562349
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Clavulanic Acid Only Product, Placebo
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years to 70 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 1, 2024 · Synced Sep 21, 2026, 1:03 PM EDT
Completed Not applicable Interventional Results available

Does a Daily Iron Tablet Improve Anemia in Cystic Fibrosis

NCT01755455
View directory record Official record
Conditions
Cystic Fibrosis, Anemia, Iron-Deficiency
Interventions
Ferrous sulfate 325mg, Placebo
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Portland, Maine • Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Sep 21, 2026, 1:03 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Varenicline on Cigarette Self Administration

NCT00731055
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Varenicline, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 17, 2018 · Synced Sep 21, 2026, 1:03 PM EDT
Completed Phase 2 Interventional Results available

Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney

NCT00035555
View directory record Official record
Conditions
Graft Rejection, Kidney Transplantation, Renal Transplantation
Interventions
Belatacept, Cyclosporine, Mycophenolate mofetil (MMF), Corticosteroids
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2012
U.S. locations
12
States / cities
San Francisco, California • Atlanta, Georgia • Baltimore, Maryland + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2014 · Synced Sep 21, 2026, 1:03 PM EDT
Completed Phase 1Phase 2 Interventional Results available

PPARγ Agonist Treatment for Cocaine Dependence

NCT02774343
View directory record Official record
Conditions
Cocaine Use Disorder, Alcohol Use Disorder
Interventions
Pioglitazone, Placebo, Therapy, Contingency Management
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 25, 2018 · Synced Sep 21, 2026, 1:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Safety and PK Study of OLT1177 Capsules

NCT02134964
View directory record Official record
Conditions
Healthy Volunteers
Interventions
OLT1177 Capsules, Placebo Capsules
Drug
Lead sponsor
Olatec Therapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Sep 21, 2026, 1:03 PM EDT
Completed Phase 2 Interventional Results available

ALK27-001: A Study of Trospium Inhalation Powder (TrIP)Administered to Subjects With COPD

NCT00801684
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Placebo, TrIP-2D, TrIP-2SS, TrIP-2SS + Foradil
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 18, 2011 · Synced Sep 21, 2026, 1:03 PM EDT
Recruiting Phase 3 Interventional

Novel Strategies for Reducing Burn Scar Itch

NCT06801626
View directory record Official record
Conditions
Burn Scar, Itch Scarring, Wound
Interventions
Famotidine and 4% topical cromolyn sodium, Placebo
Combination Product · Other
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Sep 21, 2026, 1:03 PM EDT
Not listed Not applicable Interventional

Vitamin K to Slow Progression of Cardiovascular Disease Risk in Hemodialysis Patients

NCT03311321
View directory record Official record
Conditions
Cardiovascular Diseases, Chronic Kidney Disease Stage 3, Chronic Kidney Disease Stage 4, Chronic Kidney Disease Stage 5, Vitamin K Deficiency, Hemodialysis
Interventions
Vitamin K2 (menaquinone-7; 360-mcg/d), Placebo-Control
Dietary Supplement
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Sep 21, 2026, 1:03 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of ME3183 in Subjects With Moderate to Severe Plaque Psoriasis

NCT05268016
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
ME3183, Placebo
Drug
Lead sponsor
Meiji Pharma USA Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
14
States / cities
Rogers, Arkansas • Los Angeles, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Sep 21, 2026, 1:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Cannabis, Schizophrenia and Reward: Self-Medication and Agonist Treatment?

NCT01964404
View directory record Official record
Conditions
Schizophrenia, Dual Diagnosis, Psychotic Disorder, Cannabis Use Disorder
Interventions
Marijuana, Dronabinol, Placebo
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
263 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2021
U.S. locations
2
States / cities
Lebanon, New Hampshire • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Sep 21, 2026, 1:03 PM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy

NCT03337308
View directory record Official record
Conditions
Hyperlipidemias
Interventions
Bempedoic Acid + Ezetimibe Fixed-Dose Combination, Bempedoic Acid, Ezetimibe, Placebos
Combination Product · Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
Ames, Iowa • Nashua, New Hampshire • Statesville, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2020 · Synced Sep 21, 2026, 1:03 PM EDT
Active, not recruiting Phase 2 Interventional

A Phase 2 Clinical Trial: Xanthohumol Metabolism and Signature (XMaS) in Crohn's Disease

NCT04590508
View directory record Official record
Conditions
Crohn Disease
Interventions
Xanthohumol, Placebo
Drug · Other
Lead sponsor
National University of Natural Medicine
Other
Eligibility
21 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Sep 21, 2026, 1:03 PM EDT